CD8A and neoplasm: Therefore, utilizing a CD8-independent TCR gene rather than TCRs that are functional only in CD8+ T cells offers the potential for significantly higher clinical benefit by the direct anti-tumor effects of CD4+ T cells, and the collaborative anti-tumor effects by CD4+ and CD8+ T cells.